ArticleFrontiers in cardiovascular medicine2021
Scaffold-Free Tubular Engineered Heart Tissue From Human Induced Pluripotent Stem Cells Using Bio-3D Printing Technology
Article in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Engineering the maturation of stem cell-derived cardiomyocytes.Frontiers in bioengineering and biotechnology · 2023Pooled it
- Engineering heterogeneous tissues and organs via multi-material bioprinting: Advances, challenges, and opportunities.Acta biomaterialia · 2026Review
- Challenges and opportunities in generating microvasculature using bioprinting techniques.npj biomedical innovations · 2026Review
- Biofabrication strategies for engineered constructs in cardiovascular tissue repair.Regenerative therapy · 2026Review
- Current trends, applications, and challenges in three-dimensional bioprinting for cardiovascular disease models and therapies.iScience · 2026Review
- Left ventricular assist devices and right heart dysfunction: a review of impact mechanisms, evaluation methods, and prevention and management.Journal of cardiothoracic surgery · 2026Review
- Progressing Regenerative Medicine: Integrating Bioprinting Platforms for Stem Cell Applications.Stem cells international · 2026Review
- Review
- Building the framework for bioprinted human heart tissue: recent developments and future prospects.Regenerative medicine · 2025Review
- Three-Dimensional Bioprinting Techniques in Skin Regeneration: Current Insights and Future Perspectives.Life (Basel, Switzerland) · 2025Review
- Bioprinting approaches in cardiac tissue engineering to reproduce blood-pumping heart function.iScience · 2025Review
- Artificial intelligence-assisted organoid construction in congenital heart disease: current applications and future prospects.Frontiers in bioengineering and biotechnology · 2025Review
- Application of human cardiac organoids in cardiovascular disease research.Frontiers in cell and developmental biology · 2025Review
- Advancing Cardiac Organoid Engineering Through Application of Biophysical Forces.IEEE reviews in biomedical engineering · 2024Article
- Bridging the Gap: Advances and Challenges in Heart Regeneration from In Vitro to In Vivo Applications.Bioengineering (Basel, Switzerland) · 2024Review
- Recent Advances in Hydrogel-Based 3D Bioprinting and Its Potential Application in the Treatment of Congenital Heart Disease.Biomolecules · 2024Review
- Advancements in tissue engineering for cardiovascular health: a biomedical engineering perspective.Frontiers in bioengineering and biotechnology · 2024Review
- Bioprinted vascular tissue: Assessing functions from cellular, tissue to organ levels.Materials today. Bio · 2023Review
- Nanoengineering of gold nanoribbon-embedded isogenic stem cell-derived cardiac organoids.RSC advances · 2023Article
- Biological Scaffolds for Congenital Heart Disease.Bioengineering (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Engineered heart tissues (EHTs) that are fabricated using human induced pluripotent stem cells (hiPSCs) have been considered as potential cardiac tissue substitutes in case of heart failure. In the present study, we have created hiPSC-derived cardiac organoids (hiPSC-COs) comprised of hiPSC-derived cardiomyocytes, human umbilical vein endothelial cells, and human fibroblasts. To produce a beating conduit for patients suffering from congenital heart diseases, we constructed scaffold-free tubular EHTs (T-EHTs) using hiPSC-COs and bio-3D printing with needle arrays. The bio-3D printed T-EHTs were cut open and transplanted around the abdominal aorta as well as the inferior vena cava (IVC) of NOG mice. The transplanted T-EHTs were covered with the omentum, and the abdomen was closed after completion of the procedure. Additionally, to compare the functionality of hiPSC-COs with that of T-EHTs, we transplanted the former around the aorta and IVC as well as injecting them into the subcutaneous tissue on the back of the mice. After 1 m of the transplantation procedures, we observed the beating of the T-EHTs in the mice. In histological analysis, the T-EHTs showed clear striation of the myocardium and vascularization compared to hiPSC-COs transplanted around the aorta or in subcutaneous tissue. Based on these results, bio-3D-printed T-EHTs exhibited a better maturation
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.